abstract |
Compositions and methods for treating diseases or conditions caused or exacerbated by S100A9 activity, such as myelodysplastic syndrome (MDS), using compositions comprising an effective amount of a CD33 / S100A9 inhibitor Disclose. [Selection] Figure 1A |